View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Adam Karlsson ... (+2)
  • Adam Karlsson
  • Gonzalo Castanon

Nanexa AB - Q3 report: back to the clinic soon

Encouraging progress on BD, litigation, and clinical front Opens for making NEX-18 superior to Vidaza Co. sees good opportunities for securing needed funding

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Gonzalo Castanon

Nanexa AB - Nanexa announces NEX-22 project

NEX-22: Liraglutide for type 2 diabetes (T2D) Liraglutide (Novo’s Victoza) DKK 15bn in 2021 Preclinical studies ongoing, clinical trial expected 2023

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Gonzalo Castanon

Nanexa AB - Q2 report

New facility receives GMP certification Developed first formulations with mAbs Neutral share price reaction expected today

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Gonzalo Castanon

Nanexa AB - Getting ready for its comeback

New pilot plant lays foundation for licensing agreements NEX-18 programme pause pushes approvals to ‘28 Updated valuation with new fair value range of SEK 3-9

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Gonzalo Artiach

Nanexa AB - PharmaShell patent granted by EPO

Covers manufacturing method and resulting products Good timing with recent completion of new plant Raises appeal of PharmaShell for potential partners

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Gonzalo Artiach

Nanexa AB - Q1’22 Report

Neutral reaction expected to uneventful report NEX-18 to re-enter clinical development in ’23 Patent litigation case moves in Nanexa’s favour

Adam Karlsson
  • Adam Karlsson

Nanexa AB - Q4 Report

NEX-18 will re-enter a new clinical trial in ‘23 Financials Implications for the share

Adam Karlsson
  • Adam Karlsson

Nanexa AB - Q3 Report

NEX-18 study pause still top of mind Big Pharma evaluation deal weighs up a tough quarter Share price implications

Adam Karlsson
  • Adam Karlsson

Nanexa AB - NEX-18 study put on pause

Moderate injection site skin reactions triggers study pause Nanexa believes it can be resolved and the study resumed… …but timeline remains uncertain

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Viktor Sundberg

Nanexa AB - Q2’21 Report

Important events during and after the quarter Financials Implications for the share

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Viktor Sundberg

Nanexa AB - Nanexa brings US patent suit against VitriVax

Claims vaccine-developer infringes several patents Initial assessment suggests suit has potential Amicable solution probable but raises some uncertainty

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch